Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti, Roger Echols, Yuko Matsunaga, Mari Ariyasu, Yohei Doi, Ricard Ferrer, Thomas P. Lodise, Thierry Naas, Yoshihito Niki, David L. Paterson, Simon Portsmouth, Julián Torre‐Cisneros, Kiichiro Toyoizumi, Richard G. Wunderink, Tsutae Den Nagata